GENETAG TECHNOLOGY, INC

Atlanta, GA · Medtech · Private

DDS probe array for detecting drug-resistant HBV and HCV variants via PCR amplicon analysis

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · genetagtech.com

Sector: Medtech
Headquarters: Atlanta, GA
Total capital: $4.4M

Federal grants: $4.4M; 18 awards · 2015–2022; Rank in peer group#20 of 79
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 2 pending

Capital timeline

Latest events

Jul 2022Federal grantHealth and Human S · Phase I · Developing a multiplex diagnostic test for SNPs related to dry eye disease$258K
Feb 2021Federal grantHealth and Human S · Phase I · Detecting drug-resistant HBV and HCV variants using a DDS probe array$253K
Feb 2021Federal grantHealth and Human S · Phase I · Detecting drug-resistant HBV and HCV variants using a DDS probe array$253K
Jan 2020Federal grantHealth and Human S · Phase I · Super-sensitive detection of universal markers of allograft rejection$243K
Jan 2020Federal grantHealth and Human S · Phase I · Super-sensitive detection of universal markers of allograft rejection$243K
Sep 2019Federal grantHealth and Human S · Phase I · Super-sensitive detection of BCR-ABL mutants driving CML recurrence$243K
Sep 2019Federal grantHealth and Human S · Phase I · Super-sensitive detection of BCR-ABL mutants driving CML recurrence$243K

Show 11 earlier federal awards

Aug 2019Federal grantHealth and Human S · Phase I · Detecting species-specific bacterial meningitis markers with iDDS probes$225K
Aug 2019Federal grantHealth and Human S · Phase I · Detecting species-specific bacterial meningitis markers with iDDS probes$225K
May 2019Federal grantHealth and Human S · Phase I · Super-sensitive detection of EGFR mutants driving lung cancer recurrence$243K
Mar 2019Federal grantHealth and Human S · Phase I · Super-sensitive detection of EGFR mutants driving lung cancer recurrence$243K
Sep 2017Federal grantHealth and Human S · Phase I · Blood biopsy test for pan-cancer mutations with error-checking probes$243K
Jan 2017Federal grantHealth and Human S · Phase I · Discriminating viral and bacterial meningitis infections with iDDS probes$243K
Jan 2017Federal grantHealth and Human S · Phase I · Discriminating viral and bacterial meningitis infections with iDDS probes$243K
Aug 2015Federal grantHealth and Human S · Phase I · iDDS probes detecting IDH mutants in brain cancer$243K
Aug 2015Federal grantHealth and Human S · Phase I · iDDS probes detecting IDH mutants in brain cancer$243K
Jul 2015Federal grantHealth and Human S · Phase I · Novel probes detecting ROS1,ALK and RET fusions and mutations in NSCLC$243K
Jul 2015Federal grantHealth and Human S · Phase I · Novel probes detecting ROS1,ALK and RET fusions and mutations in NSCLC$243K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 79 peers

Line = median

Medtech · Instrument

Federal grants#20 · top 25%
Linked publications#5 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2

PendingDual Probe:antiprobe Compositions For Dna And Rna DetectionUSPTOApplication PCTUS2014031898
PendingProbe-antiprobe Compositions And Methods For Dna Or Rna DetectionUSPTOApplication PCTUS2007018167

Recent research by its founders

Collective Forgetting: Textbooks and the Paris Commune in the Early Third Republic20210 cites
Lung cancer liquid biopsy assays by qPCR using iDDS probe and Wild Terminator methods.20180 cites
Comparison of direct smear and chemical extraction methods for MALDI-TOF mass spectrometry identification of clinical relevant anaerobic bacteria20177 cites

FOXO TECHNOLOGIES INC.Similar federal contract value in Medtech · null in contracts
ACTIVITY RHYTHM SOLUTIONS CORPORATIONSimilar federal contract value in Medtech · null in contracts
StimuSIL, Inc.Similar federal contract value in Medtech · null in contracts
IMBED BIOSCIENCES INCSimilar federal contract value in Medtech · null in contracts
Cadense, Inc.Similar federal contract value in Medtech · null in contracts
Pulse Therapeutics, Inc.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.